Cyclo Therapeutics (CYTH) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Rafael Holdings Targets Vote on Cyclo Therapeutics Merger in 1Q>RFL
Dow JonesDec 11 07:03 ET
Express News | Rafael Holdings Reports First Quarter Fiscal 2025 Financial Results
ReutersDec 11 07:00 ET
Press Release: Rafael Holdings Reports First Quarter Fiscal 2025 Financial Results
Dow JonesDec 11 07:00 ET
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
BenzingaDec 4 16:06 ET
10-K/A: Annual report (Amendment)
SECNov 26 16:34 ET · Announcements
Niemann-Pick Disease Pipeline Market Research 2024: Comprehensive Insights About 12+ Drugs Featuring Cyclo Therapeutics, Azafaros, IntraBio
Yahoo FinanceNov 21 04:13 ET

Comments

Teddy123

Dec 10 03:43

8k filed few days back

$Cyclo Therapeutics (CYTH.US)$
Item 1.01.
Entry into a Material Definitive Agreement.

On December 5, 2024, Cyclo Therapeutics, Inc., a Nevada corporation (the “Company”), entered into a Sixth Amended and Restated Note Purchase Agreement (the “Agreement”) with Rafael Holdings, Inc., a Delaware corporation (“Rafael”), pursuant to which the Company issued and sold a convertible promissory note in the principal amount of $1,000,000.00 (the “Note”) to Rafael. The Agreemen...

Teddy123

Nov 14 08:30

Cyclo Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

$Cyclo Therapeutics (CYTH.US)$
GAINESVILLE, Fla.--(BUSINESS WIRE)-- Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today reported its financial results for the third quarter 2024 and provided a business update...

Teddy123

Nov 8 17:17

Note matures on Dec21

$Cyclo Therapeutics (CYTH.US)$

Teddy123

Oct 9 08:16

Notice of delisting

$Cyclo Therapeutics (CYTH.US)$

Teddy123

Oct 9 01:36

Cyclo Therapeutics secures $3 million in funding from Rafael

$Cyclo Therapeutics (CYTH.US)$
EditorLina Guerrero
Published 10/08/2024, 05:25 PM
Cyclo Therapeutics, Inc., a biopharmaceutical company, announced today that it has entered into a material definitive agreement with Rafael Holdings, Inc., securing a new convertible promissory note worth $3 million. This agreement amends previous arrangements, extending the maturity date of existing notes and aligning them with the new note's terms.
On ...

CYTH Cyclo Therapeutics

Trade Overview

Capital Trend

News

Comments